Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.

Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen-positive patients in Japan. Because one-fourth of cases develop into fulminant hepatic failure and mortality is 100%, management of HBV reactivation in patients with resolved HBV infection should be discussed.

[1]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[2]  K. Tadokoro,et al.  Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. , 2006, Journal of virological methods.

[3]  Ding‐Shinn Chen,et al.  Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. , 2006, Gastroenterology.

[4]  T. Umemura,et al.  Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region , 2006, European journal of haematology.

[5]  R. Ueda,et al.  Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection , 2006, Hepatology.

[6]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Luk,et al.  Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. , 2006, Gastroenterology.

[8]  T. Umemura,et al.  Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. , 2006, Internal medicine.

[9]  Y. Hiasa,et al.  Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. , 2006, Internal medicine.

[10]  J. Angel,et al.  Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  U. Steinbrecher,et al.  Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations , 2005, Leukemia & lymphoma.

[12]  P. Aiello,et al.  HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[13]  W. Yeo,et al.  Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[14]  T. Mok,et al.  Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Su,et al.  Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy , 2004, Annals of Hematology.

[16]  D. Fong,et al.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.

[17]  William M. Lee,et al.  Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. , 2003, The Journal of infectious diseases.

[18]  E. Thiel,et al.  Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. , 2003, Blood.

[19]  M. Aljurf,et al.  Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease , 2002, Bone Marrow Transplantation.

[20]  I. Dervite,et al.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. , 2001, The New England journal of medicine.

[21]  T. Okanoue,et al.  A case‐control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C , 2001, Hepatology.

[22]  T. Okanoue,et al.  A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. , 2001, Hepatology.

[23]  C. Rieux,et al.  Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. , 1998, Transplantation.

[24]  T. Takayama,et al.  Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection , 1994 .

[25]  E. Tanaka,et al.  Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. , 1994, Gastroenterology.

[26]  F. Chisari,et al.  Hepatitis B virus persistence after recovery from acute viral hepatitis. , 1994, The Journal of clinical investigation.

[27]  J. Hoofnagle,et al.  Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B , 1993, Hepatology.

[28]  A. Mason,et al.  Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. , 1992, Gastroenterology.

[29]  Christopher Anderson,et al.  More questions than answers , 1991, Nature.

[30]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .

[31]  J. Hoofnagle,et al.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. , 1982, Annals of internal medicine.

[32]  J. Hoofnagle,et al.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. , 1981, Annals of internal medicine.

[33]  A. Zuckerman,et al.  FULMINANT HEPATIC FAILURE IN LEUKAEMIA AND CHORIOCARCINOMA RELATED TO WITHDRAWAL OF CYTOTOXIC DRUG THERAPY , 1975, The Lancet.

[34]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.